CEREMH (Centre de ressources et d'innovation mobilité handicap)
Vélizy-Villacoublay, 78140, France
NCT Number: NCT05909774
The loss of standing and walking capabilities in a paraplegic person is most often the result of damage to the spinal cord, either traumatic (accidental) or pathological and has both a somatic and a psychological impact on the quality of life, the risk of depression, and the difficulty of socio-professional reintegration in a society that is not adapted to people with disabilities.
A motorized mechanical exoskeleton is an external device intended to compensate for a muscular or neurological deficiency enabling paraplegics to stand and walk again. The Atalante exoskeleton, designed by Wandercraft company allows patients to stand upright and walk without the aid of crutches.
This early study was the first clinical investigation of the Atalante exoskeleton performed early in the development. It was used to evaluate the device design concept with respect to initial clinical safety and device functionality and guided further device modifications.
Looking for future studies?
Notify Me18 year–60 year
All sexes
Interventional
Not applicable
Vélizy-Villacoublay, 78140, France
The aim of this study was to test the use of the Atalante exoskeleton on 10 patients with complete motor paraplegia (ASIA A and B) with a level of injury between T6 and S1.
In this multi-centric clinical trial, patients were asked to perform between 1 and 2 days of training with Atalante exoskeleton including device training and evaluations (up to 9 hours of training and 3 hours of evaluation per patient).
The primary objective of this study was to assess patients' ability to walk straight- for 10 meters with the Atalante exoskeleton during 10-meters walk test (10MWT).
Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.
The secondary objectives focused on performance evaluation with the Atalante exoskeleton. The assessments performed were:
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The "continuous" walk is smoother and more physiologic than the "push and swing" walk
Other names: Test with Atalante exoskeleton in "push and swing" walk type
Time frame: Day 2
Within-group differences between the Atalante exoskeleton and the usual walking aid used by the patient in the success rate of the 10MWT were compared by a McNemar test.
Time frame: Day 2
Evaluation of walking ability through a 10mWT
Time frame: Day 2
Evaluation of verticalization ability through a success/failure test in a verticalization test (sit-to-stand movement)
Time frame: Day 2
Evaluation of static balance through a success failure in a static standing test without support from the operator (3 x 30s in a static standing position)
Time frame: Day 2
Evaluation of dynamic balance through a success/failure in a pointing test performed in a standing position without support from the operator (3 pointing sequences)
Time frame: Day 2
Static balance test with measurement of center of pressure displacement
Time frame: Day 2
Dynamic balance test with measurement of the average surface area under the (Center of Pressure position, Center of Pressure velocity) curve
Time frame: Day 2
Evaluation of perceived effort by the patient through a Borg CR-10 scale
Time frame: Day 2
Evaluation of perceived safety by the patient through a 7-point Likert scale
Time frame: Day 2
Assessment of the patient overall satisfaction through a 7-point Likert scale
Time frame: Day 2
Comparison of the two types of walk on walking ability through the 10mWT
Time frame: Day 2
Comparison of the two types of walk on perceived effort during the 10mWT through a Borg CR-10 Scale
Time frame: Day 2
Comparison of the two types of walk on perceived safety during the 10mWT through a 7-point Likert scale
Wandercraft
Industry
Acronym: M1-M2
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07706517
Brain Damage, Chronic, Brain Diseases
Saint-Etienne, France
View Trial DetailsNCT04736849
Central Nervous System Diseases, Nervous System Diseases
Rochester, Minnesota, United States
View Trial DetailsNCT05563402
Ataxia, Autoimmune Diseases
Barcelona, Spain
View Trial DetailsNCT06294834
Nervous System Diseases, Neurologic Manifestations
Pittsburgh, Pennsylvania, United States
View Trial Details